{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:47:43Z","timestamp":1793231263371,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.03-2018-05"],"award-info":[{"award-number":["WE.03-2018-05"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022692","name":"Selfridges Group Foundation","doi-asserted-by":"publisher","award":["NR170065"],"award-info":[{"award-number":["NR170065"]}],"id":[{"id":"10.13039\/501100022692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurodegeneration"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.<\/jats:p>","DOI":"10.1186\/s13024-024-00767-z","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T03:18:14Z","timestamp":1731295094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2808-3699","authenticated-orcid":false,"given":"Marta","family":"del Campo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vermunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carel F. W.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanaika S.","family":"Hok-A-Hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Trieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk den","family":"Braber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M. W.","family":"Verberk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter J.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty M.","family":"Tijms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"key":"767_CR1","first-page":"43","volume":"12","author":"IE Jansen","year":"2019","unstructured":"Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer\u2019s disease risk. Nat Genet. 2019;12:43.","journal-title":"Nat Genet"},{"key":"767_CR2","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s43587-022-00300-1","volume":"2","author":"M del Campo","year":"2022","unstructured":"del Campo M, et al. CSF proteome profiling across the Alzheimer\u2019s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2:1040\u201353. https:\/\/doi.org\/10.1038\/s43587-022-00300-1.","journal-title":"Nat Aging."},{"key":"767_CR3","doi-asserted-by":"publisher","unstructured":"Higginbotham, L, et al. Integrated Proteomics Reveals Brain-Based Cerebrospinal Fluid Biomarkers in Asymptomatic and Symptomatic Alzheimer\u2019s Disease. Sci Adv. 2020;6:eaaz9360, 806752. https:\/\/doi.org\/10.1126\/sciadv.aaz9360.","DOI":"10.1126\/sciadv.aaz9360"},{"key":"767_CR4","doi-asserted-by":"publisher","unstructured":"Bader JM, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer \u2019 s disease. Mol Syst Biol. 2020;16(6):e9356 1\u201317. https:\/\/doi.org\/10.15252\/msb.20199356.","DOI":"10.15252\/msb.20199356"},{"key":"767_CR5","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"ECB Johnson","year":"2023","unstructured":"Johnson ECB, et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat Med. 2023;29:1979\u201388.","journal-title":"Nat Med"},{"key":"767_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S1474-4422(22)00298-8","volume":"21","author":"CR Jack","year":"2022","unstructured":"Jack CR. Advances in Alzheimer\u2019s disease research over the past two decades. Lancet Neurol. 2022;21:866\u20139.","journal-title":"Lancet Neurol"},{"issue":"1","key":"767_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13195-021-00927-z","volume":"13","author":"P van Bokhoven","year":"2021","unstructured":"van Bokhoven P, et al. The Alzheimer\u2019s disease drug development landscape. Alzheimers Res Ther. 2021;13(1):186. https:\/\/doi.org\/10.1186\/s13195-021-00927-z.","journal-title":"Alzheimers Res Ther."},{"key":"767_CR8","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13195-018-0390-y","volume":"10","author":"RER Slot","year":"2018","unstructured":"Slot RER, et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10:76.","journal-title":"Alzheimers Res Ther"},{"key":"767_CR9","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ana.25334","volume":"84","author":"IMW Verberk","year":"2018","unstructured":"Verberk IMW, et al. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol. 2018;84:648\u201358.","journal-title":"Ann Neurol"},{"key":"767_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-018-0406-7","volume":"10","author":"E Konijnenberg","year":"2018","unstructured":"Konijnenberg E, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10:75.","journal-title":"Alzheimers Res Ther"},{"key":"767_CR11","doi-asserted-by":"publisher","unstructured":"Yanaika S. Hok-A-Hin et al. Thimet Oligopeptidase as a potential CSF biomarker for Alzheimer\u2019s Disease. A cross-platform validation study. Alzheimers Dement Diagn Assess Dis Monit Press. 2023;15(3):e12456. https:\/\/doi.org\/10.1002\/dad2.12456.","DOI":"10.1002\/dad2.12456"},{"key":"767_CR12","doi-asserted-by":"publisher","unstructured":"Hok-A-Hin YS, et al. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer\u2019s disease. J Neuroinflamm.\u00a02023;20(1):107. https:\/\/doi.org\/10.1186\/s12974-023-02796-9.","DOI":"10.1186\/s12974-023-02796-9"},{"key":"767_CR13","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M del Campo","year":"2023","unstructured":"del Campo M, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer\u00b4s disease. Nat Commun. 2023;14:5635.","journal-title":"Nat Commun"},{"key":"767_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2013.03.030","volume":"153","author":"B Zhang","year":"2013","unstructured":"Zhang B, et al. Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer\u2019s Disease. Cell. 2013;153:707\u201320.","journal-title":"Cell"}],"container-title":["Molecular Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13024-024-00767-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13024-024-00767-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T17:05:00Z","timestamp":1731344700000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecularneurodegeneration.biomedcentral.com\/articles\/10.1186\/s13024-024-00767-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["767"],"URL":"https:\/\/doi.org\/10.1186\/s13024-024-00767-z","relation":{},"ISSN":["1750-1326"],"issn-type":[{"value":"1750-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"20 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Ethical Review Boards (AD CSF biobank METC number.00\u2013211) and informed consent was obtained from all subjects or their authorized representatives.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC has been an invited speaker at Eisai and Novonordisk. She is an associate editor at Alzheimer\u00b4s Research & Therapy and has been an invited writer for Springer Healthcare. LV received a grant for CORAL consortium by Olink, and has been invited speaker for Eli Lilly, and consultant for Roche. IV received a TKI Health\u2009~\u2009Holland grant for a collaborative project with OLINK and Quanterix. IV has been an invited speaker by Quanterix, funding is paid to her institution. WvF has been an invited speaker at Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, European Brain Council. WF is consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc, and Eisai. WF is member of steering cie of NovoNordisk evoke\/evoke\u2009+\u2009. WvF participated in advisory boards of Biogen MA Inc, Roche, and Eli Lilly. All funding is paid to her institution. WvF is member of the steering committee of PAVE, and Think Brain Health. WvF was associate editor of Alzheimer, Research & Therapy in 2020\/2021. WvF is associate editor at Brain. CET has a collaboration contract with ADx Neurosciences, Quanterix and Eli Lilly, performed contract research or received grants from AC-Immune, Axon Neurosciences, Bioconnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Grifols, Novo Nordisk, PeopleBio, Roche, Toyama, Vivoryon. She serves on editorial boards of Medidact Neurologie\/Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology & Neuroinflammation, and is editor of a Neuromethods book Springer. She had speaker contracts for Roche, Grifols, Novo Nordisk. The rest of the authors declare no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}